[Form 4] Intellia Therapeutics, Inc. Insider Trading Activity
Michael P. Dube, Vice President and Chief Accounting Officer of Intellia Therapeutics, Inc. (NTLA), reported a Form 4 disclosing a mandatory tax-withholding sale related to RSU vesting. On 10/01/2025 the reporting person had 1,871 shares sold (transaction code S(1)) at $17.38 per share to satisfy tax withholding obligations arising from RSU vesting. After the sale, the reporting person beneficially owned 55,266 shares. The Form 4 was signed by an attorney-in-fact and dated 10/03/2025. The filing describes the sale as non-volitional and linked solely to tax withholding.
Michael P. Dube, Vicepresidente e Responsabile della Contabilita' di Intellia Therapeutics, Inc. (NTLA), ha riportato un modulo 4 che rivela una vendita obbligatoria per trattenuta fiscale correlata alla vesting degli RSU. Il 10/01/2025 la persona reportante ha avuto 1,871 azioni vendute (codice di operazione S(1)) a $17.38 per azione per soddisfare gli obblighi di trattenuta fiscale derivanti dalla vesting delle RSU. Dopo la vendita, la persona reportante possedeva beneficamente 55,266 azioni. Il Modulo 4 è stato firmato da un procuratore e datato 10/03/2025. La presentazione descrive la vendita come non volontaria e legata unicamente alla trattenuta fiscale.
Michael P. Dube, Vicepresidente y Director de Contabilidad de Intellia Therapeutics, Inc. (NTLA), informó un Formulario 4 que revela una venta obligatoria de retención de impuestos relacionada con el vesting de RSU. El 01/10/2025 la persona reportante tuvo 1,871 acciones vendidas (código de transacción S(1)) a $17.38 por acción para satisfacer las obligaciones de retención de impuestos derivadas del vesting de RSU. Después de la venta, la persona reportante poseía beneficiosamente 55,266 acciones. El Formulario 4 fue firmado por un apoderado y fechado el 03/10/2025. La presentación describe la venta como no voluntaria y vinculada únicamente a la retención de impuestos.
마이클 P. 듀브는 Intellia Therapeutics, Inc. (NTLA)의 부사장 겸 최고 회계 책임자로서 RSU vesting과 관련된 의무적 세금 원천징수 매도를 공시하는 Form 4를 보고했습니다. 2025/10/01에 보고자은 1,871주를 매도했고 거래 코드 S(1)는 주당 $17.38로 세금 원천징수 의무를 충족하기 위해서였습니다. 매도 후 보고자는 유익하게 55,266주를 보유하게 되었습니다. Form 4는 대리인에 의해 서명되었고 2025/10/03에 날짜가 기재되어 있습니다. 제출은 이 매도를 비자발적이며 RSU vesting으로 인한 세금 원천징수에만 연결되어 있다고 설명합니다.
Michael P. Dube, Vice-président et Directeur de la comptabilité chez Intellia Therapeutics, Inc. (NTLA), a déclaré un Form 4 révélant une vente obligatoire de retenue d'impôt liée au vesting des RSU. Le 01/10/2025, la personne qui déclare a vendu 1 871 actions (code de transaction S(1)) à $17,38 par action pour satisfaire les obligations de retenue d'impôt résultant du vesting des RSU. Après la vente, la personne déclarant détenait officiellement 55 266 actions. Le Form 4 a été signé par un mandataire et daté du 03/10/2025. Le document décrit la vente comme non volontaire et liée uniquement à la retenue d'impôt.
Michael P. Dube, Vizepräsident und Chief Accounting Officer von Intellia Therapeutics, Inc. (NTLA), berichtete über ein Form 4, das einen obligatorischen steuerlichen Quellenabzug in Zusammenhang mit RSU-Vesting offenlegt. Am 10/01/2025 verzeichnete die meldende Person den Verkauf von 1.871 Aktien (Transaktionscode S(1)) zu $17,38 pro Aktie, um die aus dem RSU-Vesting resultierenden Steuerabzugsverpflichtungen zu erfüllen. Nach dem Verkauf besaß die meldende Person vorteilhaft 55.266 Aktien. Das Form 4 wurde von einem Bevollmächtigten unterzeichnet und datiert auf den 03/10/2025. Die Einreichung beschreibt den Verkauf als nicht freiwillig und ausschließlich mit dem Steuerabzug verbunden.
مايكل ب. دوبا، نائب الرئيس ورئيس المحاسبة في Intellia Therapeutics, Inc. (NTLA)، أبلغ عن نموذج 4 يكشف عن بيع إلزامي تخصيص ضريبي مرتبط بإتمام vesting لـ RSU. في 10/01/2025 قامت الشخص المُبلغ عنهم ببيع 1,871 سهماً (رمز الصفقة S(1)) بسعر $17.38 للسهم الواحد لتلبية الالتزامات بالاقتطاع الضريبي الناتجة عن vesting RSU. بعد البيع، امتلك المُبلغ عنهم فعلياً 55,266 سهماً. وقع النموذج 4 بواسطة وكيل وتاريخ 10/03/2025. وتصف الوثيقة البيع بأنه غير طوعي ويرتبط فقط بالاقتطاع الضريبي.
Michael P. Dube，Intellia Therapeutics, Inc. (NTLA) 的副总裁兼首席会计官，提交了 Form 4，披露与 RSU 授予相关的强制代扣税出售。于 2025/10/01，该披露人有 1,871 股被出售（交易代码 S(1)），每股价格为 $17.38，以满足 RSU 授予相关的税收代扣义务。出售后，该披露人实际持有 55,266 股。 Form 4 由代理人签署，日期为 2025/10/03。 filing 将该出售描述为非自愿且仅与税收代扣相关。
- None.
- None.
Insights
Routine insider tax-withholding sale; shows compliance with reporting rules.
The Form 4 documents a mandatory sell-to-cover on 10/01/2025 for 1,871 shares at $17.38, which is explicitly described as non-volitional and tied to RSU vesting. This indicates the officer followed standard equity compensation procedures rather than executing a discretionary trade.
The timely filing and signature by an attorney-in-fact on 10/03/2025 reflect adherence to Section 16 reporting requirements, reducing governance or disclosure risk for the issuer.
Sell-to-cover reduces holdings modestly; no new compensation terms disclosed.
The sale satisfied tax withholding from vested RSUs; the report lacks any new grants, option exercises, or changes to the equity plan. The officer's post-transaction holding of 55,266 shares remains disclosed, providing clarity on retained insider exposure.
No information in the filing indicates additional planned sales or a 10b5-1 plan; the transaction is presented solely as a withholding mechanism.
Michael P. Dube, Vicepresidente e Responsabile della Contabilita' di Intellia Therapeutics, Inc. (NTLA), ha riportato un modulo 4 che rivela una vendita obbligatoria per trattenuta fiscale correlata alla vesting degli RSU. Il 10/01/2025 la persona reportante ha avuto 1,871 azioni vendute (codice di operazione S(1)) a $17.38 per azione per soddisfare gli obblighi di trattenuta fiscale derivanti dalla vesting delle RSU. Dopo la vendita, la persona reportante possedeva beneficamente 55,266 azioni. Il Modulo 4 è stato firmato da un procuratore e datato 10/03/2025. La presentazione descrive la vendita come non volontaria e legata unicamente alla trattenuta fiscale.
Michael P. Dube, Vicepresidente y Director de Contabilidad de Intellia Therapeutics, Inc. (NTLA), informó un Formulario 4 que revela una venta obligatoria de retención de impuestos relacionada con el vesting de RSU. El 01/10/2025 la persona reportante tuvo 1,871 acciones vendidas (código de transacción S(1)) a $17.38 por acción para satisfacer las obligaciones de retención de impuestos derivadas del vesting de RSU. Después de la venta, la persona reportante poseía beneficiosamente 55,266 acciones. El Formulario 4 fue firmado por un apoderado y fechado el 03/10/2025. La presentación describe la venta como no voluntaria y vinculada únicamente a la retención de impuestos.
마이클 P. 듀브는 Intellia Therapeutics, Inc. (NTLA)의 부사장 겸 최고 회계 책임자로서 RSU vesting과 관련된 의무적 세금 원천징수 매도를 공시하는 Form 4를 보고했습니다. 2025/10/01에 보고자은 1,871주를 매도했고 거래 코드 S(1)는 주당 $17.38로 세금 원천징수 의무를 충족하기 위해서였습니다. 매도 후 보고자는 유익하게 55,266주를 보유하게 되었습니다. Form 4는 대리인에 의해 서명되었고 2025/10/03에 날짜가 기재되어 있습니다. 제출은 이 매도를 비자발적이며 RSU vesting으로 인한 세금 원천징수에만 연결되어 있다고 설명합니다.
Michael P. Dube, Vice-président et Directeur de la comptabilité chez Intellia Therapeutics, Inc. (NTLA), a déclaré un Form 4 révélant une vente obligatoire de retenue d'impôt liée au vesting des RSU. Le 01/10/2025, la personne qui déclare a vendu 1 871 actions (code de transaction S(1)) à $17,38 par action pour satisfaire les obligations de retenue d'impôt résultant du vesting des RSU. Après la vente, la personne déclarant détenait officiellement 55 266 actions. Le Form 4 a été signé par un mandataire et daté du 03/10/2025. Le document décrit la vente comme non volontaire et liée uniquement à la retenue d'impôt.
Michael P. Dube, Vizepräsident und Chief Accounting Officer von Intellia Therapeutics, Inc. (NTLA), berichtete über ein Form 4, das einen obligatorischen steuerlichen Quellenabzug in Zusammenhang mit RSU-Vesting offenlegt. Am 10/01/2025 verzeichnete die meldende Person den Verkauf von 1.871 Aktien (Transaktionscode S(1)) zu $17,38 pro Aktie, um die aus dem RSU-Vesting resultierenden Steuerabzugsverpflichtungen zu erfüllen. Nach dem Verkauf besaß die meldende Person vorteilhaft 55.266 Aktien. Das Form 4 wurde von einem Bevollmächtigten unterzeichnet und datiert auf den 03/10/2025. Die Einreichung beschreibt den Verkauf als nicht freiwillig und ausschließlich mit dem Steuerabzug verbunden.
FAQ
What did Intellia (NTLA) insider Michael P. Dube report on Form 4?
Was the sale by the NTLA insider voluntary?
When was the Form 4 for NTLA filed and who signed it?
How many shares does Michael P. Dube own after the transaction?
What was the sale price per share on the reported transaction?
